MGMaria Fernanda Brandão Resende Guimarães

Maria Fernanda Brandão Resende Guimarães

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Fernanda Brandão Resende Guimarães has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advances and barriers in gender equity within Brazilian rheumatology: a two-year follow-up study

    by Mariana Peixoto Guimarães Ubirajara Souza, Ricardo Machado Xavier, Odirlei Monticielo, Latika Gupta, Pavel Ovseiko, Maria Fernanda Guimarães, Grace Wright, Laura Coates, Vikas Agarwal, Viviane Angelina de Souza, et al.

    Introduction: Gender equity is increasingly recognized as essential to integrity and sustainability of the medical workforce, yet significant disparities remain. This study aims to evaluate longitudinal trends in gender equity within Brazilian rheumatology, focusing on career advancement, work-family interface, and workplace safety. Methods: This comparative cross-sectional study analyzed two self-administered, web-based surveys conducted at different moments among members of the Brazilian Society of Rheumatology (SBR), to assess temporal changes. The surveys included Reuma Equity (2022, n = 459, 67.1% women) and the Brazilian subset of the global Coalition for Health and Gender Equity (CHANGE) (2024, n = 301, 74.4% women). Statistical analyses included Pearson’s chi-square, Fisher’s exact, and Mann–Whitney tests, with a significance level set at p ≤ 0.05. Results: In both moments, female rheumatologists were younger [2022: OR 3.7, (95% CI 2.2–6.4, p = 0.001); 2024: OR 4.3, (95% CI 2.2–8.6, p < 0.001)], carried a greater burden of domestic labor [2022: OR 2.8, (95% CI 1.8–4.3, p < 0.001); 2024: OR 2.8, (95% CI 1.5–5.1, p < 0.001)], and men were more likely to occupy prominent positions at national congresses [2022: OR 2.3, (95% CI 1.5–3.4, p < 0.001); 2024: OR 2.1, (95%CI 1.3–3.6, p = 0.005)]. There was an increase in the probability of women being more likely to refuse career progression for family-related reasons [2022: OR 2.1, (95% CI 1.2–3.7, p = 0.038); 2024: OR 3.2, (95% CI 1.8–6.1, p < 0.001)], and a decrease in reported rates of sexual harassment [2022: OR 4.2, (95% CI 2.5–6.9, p < 0.001); 2024: OR 2.6, (95% CI 1.4–4.6, p = 0.002)]. Gender disparities in medical visit fees (lower fees: 69.2% women and 57.6% men, p = 0.043), and medical visit duration (longer appointments: 78.2% women and 69.5% men, p = 0.014) observed in 2022 disappeared by 2024 ( p = 1.00, p = 0.318). Conclusion: Although representation in Brazilian rheumatology is increasing, women continue to shoulder disproportionate domestic responsibilities, decline career opportunities more often, and experience higher rates of harassment. Even so, improvements were observed in professional indicators and in the male’ views, suggesting gradual progress toward gender equity.

  • Open Access

    Unveiling Clinical Phenotypes in Chronic Chikungunya Disease: Insights from a Brazilian Observational Study

    by Karen Santos Lima, Adriane Paz Rocha, Alice Lanna Damásio Castro, Anna Carolina Faria Moreira Gomes Tavares, Flávia Patrícia Sena Teixeira Santos, Gilda Aparecida Ferrreira, Livia Barbara Cordeiro Alves, Josiane Lino dos Santos Frattari, Juliana Froeseler Fittipaldi, Lucas Borba Paulino Coelho, et al.

    Chronic chikungunya disease (CCD) affects approximately 30–50% of infected individuals and is associated with persistent inflammatory arthritis, chronic pain, and long-term functional disability. We conducted a prospective observational cohort study including 584 patients with laboratory-confirmed chikungunya infection, evaluated between 3 and 12 months after acute infection, to better understand the natural history, risk factors, clinical presentation, and treatment patterns of CCD. Here, we present a cross-sectional analysis derived from this cohort. Older age, female sex, and higher body mass index were identified as major risk factors for CCD. Four distinct clinical phenotypes were identified: Axial (12.2%), defined by inflammatory axial pain regardless of peripheral manifestations; Oligoarthritis (18.1%), defined by fewer than four swollen joints; Polyarthritis (10.6%), defined by four or more swollen joints; and Pain without Swelling (70.4%), characterized by myalgia and/or arthralgia in the absence of objective inflammatory findings on physical examination. The axial phenotype could overlap with peripheral phenotypes, whereas oligoarthritis, polyarthritis, and pain without swelling were mutually exclusive categories. These phenotypes differed substantially in symptom burden and clinical impact. Patients with the Pain without Swelling phenotype had longer symptom duration, whereas Axial and Polyarthritis phenotypes were associated with greater functional impairment and higher disease burden. These findings reinforce the clinical heterogeneity of CCD and support the potential value of phenotype-based approaches for clinical management and future therapeutic research.

  • Open Access

    Are global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients

    by Lucas Castro Pires, Alisson Pugliesi, Cleandro Pires de Albuquerque, Vitor Alves Cruz, Manoel Barros Bertolo, Ana Paula Monteiro Gomides Reis, Rina Dalva Neubarth Giorgi, Leticia Rocha Pereira, Sebastião Cezar Radominski, Ivanio Alves Pereira, et al.

    Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population. Methods: We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis. Results: The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively. Conclusion: In our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.

  • Open Access

    Evaluation of screening methods for preclinical interstitial lung disease associat-ed with rheumatoid arthritis

    by Ana Luisa Bagno de Almeida1, Mariana Drummond Martins Lima1, Maria Fernanda B. Resende Guimarães1, Eliane Viana Mancuzo1

  • Open Access

    Treat-to-target na osteoporose: onde estamos?

    by Beatriz Mota Tiburcio, Flávia Patrícia Sena Teixeira Santos, Maria Fernanda Brandão Resende Guimarães

    A estratégia Treat-to-target (T2T) envolve a definição de um alvo terapêutico, a escolha da medicação adequada, a monitorização contínua da resposta do tratamento e o acompanhamento sequencial visando monitorar respostas e adequar o tratamento para atingir as metas definidas. É um conceito novo que está sendo aplicado na osteoporose, uma doença crônica, de tratamento prolongado, que ainda é subdiagnosticada e subtratada.Dever ser proposto um tratamento individualizado, levando em consideração a presença e número de fraturas clínicas ou radiográficas por meio de radiografias de coluna, o risco de novas fraturas, a densidade mineral óssea e o T-score por meio da densitometria óssea. Uma vez que o paciente tem seu risco estratificado e suas metas definidas, deve seguir pela escolha terapêutica adequada, seja com a introdução de um antirreabsortivos ou de um anabólico. A resposta ao tratamento e a busca por atingir o alvo proposto devem ser continuamente monitorizadas, com radiografias e densitometrias sequenciais para avaliar a manutenção ou a troca do tratamento conforme os resultados encontrados. O objetivo final do T2T é melhorar o tratamento da osteoporose e, consequentemente, reduzir o número de fraturas novas. .

  • Open Access

    Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort

    by Karina Rossi Bonfiglioli, Ana Cristina de Medeiros Ribeiro, Ana Paula Carnieletto, Ivânio Pereira, Diogo Souza Domiciano, Henrique Carriço da Silva, Alisson Pugliesi, Leticia Rocha Pereira, Maria Fernanda Resende Guimarães, Rina Dalva Neubarth Giorgi, et al.

    Introduction: Although Rheumatoid Arthritis (RA) extra-articular manifestations (ExtRA) occurrence has been decreasing over time, they are still a major mortality risk factor for patients. Objective: To determine the prevalence of ExtRA in a large cohort, and its association with demographic and clinical variables. Method: Cross-sectional and observational study, based on a multi-centric database from a prospective cohort, in which 11 public rheumatology centres enrolled RA patients (1987 ARA or 2010 ACR-EULAR). Data collection began in 08-2015, using a single online electronic medical record. Continuous variables were compared using Mann–Whitney U-test, and Fisher’s exact test or chi-square test, as appropriate, were used for categorical variables. The level of significance was set at 5% (p < 0.05). Results: 1115 patients were included: 89% women, age [mean ± SD] 58.2 ± 11.5 years, disease duration 14.5 ± 12.2 years, positive Rheumatoid Factor (RF, n = 1108) in 77%, positive anti-cyclic citrullinated peptide (ACPA, n = 477) in 78%. Regarding ExtRA, 334 occurrences were registered in 261 patients, resulting in an overall prevalence of 23.4% in the cohort. The comparison among ExtRA and Non-ExtRA groups shows significant higher age (p < 0.001), disease duration (p < 0.001), RF high titers (p = 0.018), Clinical Disease Activity index (CDAI) (p < 0.001), Disease Activity Index 28 (DAS 28) (p < 0.001), and Health Assessment Questionnaire (HAQ) (p < 0.001) in ExtRA group. Treatment with Azathioprine (p = 0.002), Etanercept (p = 0.049) Glucocorticoids (GC) (‘p = 0.002), and non-steroidal anti-inflammatory drugs (NSAIDs) (p < 0.001) were more frequent in ExtRA group. Conclusions: ExtRA manifestations still show an expressive occurrence that should not be underestimated. Our findings reinforce that long-term seropositive disease, associated with significant disability and persistent inflammatory activity are the key factors related to ExtRA development.


  • Open Access

    Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study

    by Isabela Araújo Santos, Renê Donizeti Ribeiro de Oliveira, Sergio Couto Luna Almeida, Ana Beatriz Vargas-Santos, Rodrigo Balbino Chaves Amorim, Ana Paula Monteiro Gomides, Cleandro Pires de Albuquerque, Manoel Barros Bertolo, Maria Fernanda Brandão Resende Guimarães, Maria Raquel da Costa Pinto, et al.

    Introduction: Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment. However, there is no definition of the best index to assess disease activity in clinical practice. Objectives: To compare the residual activity among the indices with the ACR/EULAR remission criteria (Boolean method) to identify the most feasible for assessing remission in daily practice, also considering correlation and concordance, sensibility, and specificity. Patients and methods: We selected 1116 patients with established RA from the real-life rheumatoid arthritis study database—REAL. The composite disease activity indices—DAS28-ESR, DAS28-CRP, SDAI, and CDAI–and their components were compared to the Boolean method to identify residual activity using binomial regression. The indices were analyzed for correlation and agreement using the Spearman index and weighted kappa. The chi-square test evaluated sensibility and specificity for remission based on the Boolean method. Results: DAS28-CRP overestimated remission and confirmed higher residual activity than SDAI and CDAI. The indices showed good correlation and agreement, with a better relationship between SDAI and CDAI (k:0,88). CDAI and SDAI showed higher sensitivity and specificity for remission based on the Boolean method. CDAI was performed in 99% of patients, while DAS28 and SDAI were completed in approximately 85%. Conclusions: Although all composite indices of activity can be used in clinical practice and showed good agreement, CDAI and SDAI have better performance in evaluating remission based on the Boolean method, showing less residual activity and higher sensibility and specificity. In addition, CDAI seems to be more feasible for disease activity evaluation in daily clinical practice, especially in developing countries.


  • Open Access

    JAK INHIBITORS VS BIOLOGICS FOR RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS FROM AN ONGOING OBSERVATIONAL REAL-WORLD PROSPECTIVE COHORT

    by Lucas Moyses Carvalho de Oliveira, Maria Fernanda Brandão Resende Guimarães, Débora Cerqueira Calderaro, Maria Raquel da Costa Pinto, Matheus Tozatto Baptista Coelho, Flávio Augusto Oliveira de Medeiros, Clarice Moura Mata Machado, Carolina Ruas Freire Santos

  • Open Access

    Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force

    by Anna Carolina Faria Moreira Gomes Tavares, Ana Karla Guedes de Melo, Vítor Alves Cruz, Viviane Angelina de Souza, Joana Starling de Carvalho, Ketty Lysie Libardi Lira Machado, Lilian David de Azevedo Valadares, Edgard Torres dos Reis Neto, Rodrigo Poubel Vieira de Rezende, Maria Fernanda Brandão de Resende Guimarães, et al.

    Objective: To provide guidelines on the coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated rheumatic diseases (IMRD) to rheumatologists considering specific scenarios of the daily practice based on the shared-making decision (SMD) process. Methods: A task force was constituted by 24 rheumatologists (panel members), with clinical and research expertise in immunizations and infectious diseases in immunocompromised patients, endorsed by the Brazilian Society of Rheumatology (BSR), to develop guidelines for COVID-19 vaccination in patients with IMRD. A consensus was built through the Delphi method and involved four rounds of anonymous voting, where five options were used to determine the level of agreement (LOA), based on the Likert Scale: (1) strongly disagree; (2) disagree, (3) neither agree nor disagree (neutral); (4) agree; and (5) strongly agree. Nineteen questions were addressed and discussed via teleconference to formulate the answers. In order to identify the relevant data on COVID-19 vaccines, a search with standardized descriptors and synonyms was performed on September 10th, 2021, of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and LILACS to identify studies of interest. We used the Newcastle–Ottawa Scale to assess the quality of nonrandomized studies. Results: All the nineteen questions-answers (Q&A) were approved by the BSR Task Force with more than 80% of panelists voting options 4—agree—and 5—strongly agree—, and a consensus was reached. These Guidelines were focused in SMD on the most appropriate timing for IMRD patients to get vaccinated to reach the adequate covid-19 vaccination response. Conclusion: These guidelines were developed by a BSR Task Force with a high LOA among panelists, based on the literature review of published studies and expert opinion for COVID-19 vaccination in IMRD patients. Noteworthy, in the pandemic period, up to the time of the review and the consensus process for this document, high-quality evidence was scarce. Thus, it is not a substitute for clinical judgment.


  • Open Access

    Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study—Brazil

    by Maria Fernanda Brandão Resende Guimarães, Maria Raquel Da Costa Pinto, Gustavo Gomes Resende, Carla Jorge Machado, Ana Beatriz Vargas-Santos, Rodrigo Balbino Chaves Amorim, Ana Paula Monteiro Gomides, Cleandro Pires De Albuquerque, Manoel Barros Bértolo, Paulo Louzada Júnior, et al.

    Discordance between patient’s global assessment (PtGA) and physician’s global assessment (PhGA) has been described in rheumatoid arthritis (RA). Understanding the reasons for this discrepancy is important in the context of treat-to-target treatment strategy. To assess the determinants of PtGA and PhGA and factors associated with discordance between them. The REAL study included RA patients from Brazilian public health centers. Clinical, laboratory and outcomes measures were collected. PtGA and the PhGA were rated on a visual analog scale and analyzed. Three groups were defined: no discordance (difference between PtGA and PhGA within 3 cm), positive discordance (PtGA exceeding PhGA by >3 cm), and negative discordance (PtGA less than PhGA by >3 cm). Multivariate regression analysis was used to identify determinants of PtGA and PhGA and their discordance. 1115 patients (89,4% female, mean age 56.7y and median disease duration of 12.7y) were enrolled. Two factors were associated with PtGA in the final multivariate model: one point increase in the pain scale leads to an increase of 0.62 in PtGA; one point increase in HAQ increases by 9,25 points the PtGA. The factors associated with PhGA were pain scale, number of tender and swollen joints (NTJ and NSJ), positive RF, ESR, HAQ-DI and use of corticosteroids. Discordance between patient and physician was found in 30.52%: positive discordance in 24.6% and negative discordance in 5.92%. An increase of one point in the NSJ was associated with a 12% increase in the chance of negative discordance. The chance of positive discordance increased by 90% and 2% for each unit increased in HAQ-DI and pain scale respectively. Finally, the chance of positive discordance decreased by 3% for each point increased in NTJ and by 15% for each point increased in NSJ. In one-third of the assessments, there was disagreement between PtGA and PhGA (a positive discordance was found in 80% of them). Pain and function were determinants for patients to estimate disease activity, while swollen joints was the main factor related to a worse physician’s evaluation. These data show how different can be the perspectives of patients and assistants.